[go: up one dir, main page]

TN2009000142A1 - Bicyclic triazoles as protein kinase modulators - Google Patents

Bicyclic triazoles as protein kinase modulators

Info

Publication number
TN2009000142A1
TN2009000142A1 TNP2009000142A TN2009000142A TN2009000142A1 TN 2009000142 A1 TN2009000142 A1 TN 2009000142A1 TN P2009000142 A TNP2009000142 A TN P2009000142A TN 2009000142 A TN2009000142 A TN 2009000142A TN 2009000142 A1 TN2009000142 A1 TN 2009000142A1
Authority
TN
Tunisia
Prior art keywords
protein kinase
kinase modulators
bicyclic triazoles
triazoles
bicyclic
Prior art date
Application number
TNP2009000142A
Other languages
English (en)
Inventor
Pierre-Yves Bounaud
Christopher Ronald Smith
Elizabeth Anne Jefferson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of TN2009000142A1 publication Critical patent/TN2009000142A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2009000142A 2006-10-23 2009-04-15 Bicyclic triazoles as protein kinase modulators TN2009000142A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30
PCT/US2007/081841 WO2008051808A2 (fr) 2006-10-23 2007-10-18 Triazoles bicycliques en tant que modulateurs de protéine kinase

Publications (1)

Publication Number Publication Date
TN2009000142A1 true TN2009000142A1 (en) 2010-10-18

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000142A TN2009000142A1 (en) 2006-10-23 2009-04-15 Bicyclic triazoles as protein kinase modulators

Country Status (25)

Country Link
US (1) US8507489B2 (fr)
EP (1) EP2084162B1 (fr)
JP (1) JP5378222B2 (fr)
KR (1) KR20090071612A (fr)
AR (1) AR063520A1 (fr)
AU (1) AU2007309149C1 (fr)
BR (1) BRPI0717320A2 (fr)
CA (1) CA2667428A1 (fr)
CO (1) CO6190620A2 (fr)
CR (1) CR10803A (fr)
DK (1) DK2084162T3 (fr)
EA (1) EA200970403A1 (fr)
ES (1) ES2393130T3 (fr)
IL (1) IL197958A0 (fr)
MA (1) MA30871B1 (fr)
MX (1) MX2009004059A (fr)
NO (1) NO20091618L (fr)
NZ (1) NZ575336A (fr)
PE (1) PE20080893A1 (fr)
PL (1) PL2084162T3 (fr)
PT (1) PT2084162E (fr)
SV (1) SV2009003235A (fr)
TN (1) TN2009000142A1 (fr)
TW (1) TW200835492A (fr)
WO (1) WO2008051808A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (fr) 2008-09-19 2010-03-24 Institut Curie Récepteur TYRO3 de la tyrosine kinase en tant que cible thérapeutique dans le traitement d'une tumeur de la vessie
EP2356116A1 (fr) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
CA2770873A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composes hydrazone heterocycliques et leurs utilisations pour traiter le cancer et l'inflammation
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
PE20160588A1 (es) 2009-12-31 2016-07-09 Hutchison Medipharma Ltd Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EP2569315A1 (fr) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
CA2848809A1 (fr) 2011-09-15 2013-03-21 Novartis Ag 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituees en position 6 a activite tyrosine kinase
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
RU2014143213A (ru) 2012-04-03 2016-05-27 Новартис Аг Соединения ингибитора тирозинкиназы и их применение
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (fr) * 2012-12-10 2014-06-19 Abbvie Inc. Composés triazinones
WO2014164195A1 (fr) 2013-03-13 2014-10-09 Avon Products, Inc Inhibiteurs de tyrosinase
WO2014164200A1 (fr) 2013-03-13 2014-10-09 Avon Products, Inc Inhibiteurs de la tyrosinase
KR20180070715A (ko) * 2013-03-13 2018-06-26 에프. 호프만-라 로슈 아게 벤즈옥사제핀 화합물의 제조 방법
US20150152122A1 (en) * 2013-03-13 2015-06-04 Avon Products, Inc. Tyrosinase inhibitors
WO2014174478A1 (fr) 2013-04-26 2014-10-30 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
CA2910367C (fr) * 2013-05-10 2021-07-20 Jiangsu Hansoh Pharmaceutical Co., Ltd. Derive de [1,2,4]-triazole-[4,3-a]-pyridine, procede de preparation correspondant ou application medicale correspondante
CN105272995B (zh) 2015-09-24 2017-10-27 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
EP0228061A3 (fr) 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Composés céphem
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083675A2 (fr) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibiteurs de l'activite de l'akt
WO2002083139A1 (fr) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibiteurs de l'activite d'akt
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
RU2005122484A (ru) * 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
SG156685A1 (en) * 2004-07-27 2009-11-26 Sgx Pharmaceuticals Inc Fused ring heterocycle kinase modulators
PL1784396T3 (pl) 2004-08-26 2011-05-31 Pfizer Związki aminoheteroarylowe podstawione pirazolem jako inhibitory kinazy białkowej
WO2006071548A2 (fr) 2004-12-27 2006-07-06 Alcon, Inc. Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase

Also Published As

Publication number Publication date
TW200835492A (en) 2008-09-01
WO2008051808A3 (fr) 2008-07-24
MX2009004059A (es) 2009-04-27
CO6190620A2 (es) 2010-08-19
PE20080893A1 (es) 2008-08-26
PT2084162E (pt) 2012-10-09
NZ575336A (en) 2012-04-27
AR063520A1 (es) 2009-01-28
CR10803A (es) 2009-06-16
NO20091618L (no) 2009-05-22
AU2007309149A1 (en) 2008-05-02
AU2007309149C1 (en) 2013-04-04
EP2084162B1 (fr) 2012-09-12
US20090258855A1 (en) 2009-10-15
JP2010507578A (ja) 2010-03-11
PL2084162T3 (pl) 2013-01-31
IL197958A0 (en) 2009-12-24
AU2007309149B2 (en) 2012-09-06
MA30871B1 (fr) 2009-11-02
ES2393130T3 (es) 2012-12-18
DK2084162T3 (da) 2012-10-01
EA200970403A1 (ru) 2009-10-30
JP5378222B2 (ja) 2013-12-25
KR20090071612A (ko) 2009-07-01
SV2009003235A (es) 2009-10-15
CA2667428A1 (fr) 2008-05-02
BRPI0717320A2 (pt) 2013-10-22
WO2008051808A2 (fr) 2008-05-02
EP2084162A2 (fr) 2009-08-05
US8507489B2 (en) 2013-08-13

Similar Documents

Publication Publication Date Title
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
MX2009012623A (es) Moduladores de cinasa heterociclicos.
TW200833692A (en) Triazolopyridazine protein kinase modulators
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
UA104849C2 (uk) 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
TW200745109A (en) Pyrrolo-pyridine kinase modulators
NZ630719A (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
MX2009010984A (es) Moduladores de heterociclo cinasa de anillo fusionado.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
WO2008124849A3 (fr) Modulateurs de pyrrolo-pyridine kinase
WO2011115725A3 (fr) Composés d'indazole et leurs utilisations
TNSN07028A1 (en) Fused ring heterocycle kinase modulators
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
IN2014DN07384A (fr)
EA200870048A1 (ru) ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
IL193479A0 (en) Modulators of muscarinic receptors
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200734323A (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
UA101315C2 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА КАК ИНГИБИТОРЫ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
TW200745059A (en) Sulfonyl-substituted bicyclic compounds as modulators of PPAR
WO2009126335A3 (fr) Composés inhibiteurs d’ant2 et procédés d’utilisation de ceux-ci